Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.358
Filter
1.
Rev. urug. cardiol ; 37(1): e302, jun. 2022. ilus, tab
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1390042

ABSTRACT

Las amiloidosis son enfermedades causadas por el depósito patológico extracelular de un material proteico fibrilar e insoluble denominado amiloide, que puede estar vinculado a cadenas livianas (AL) o transtirretina (TTR). La amiloidosis cardíaca provoca una cardiomiopatía restrictiva de carácter progresivo caracterizada por falla cardíaca con función sistólica relativamente preservada, que se asocia a elevada mortalidad. Aunque el diagnóstico definitivo tradicionalmente se basa en la biopsia endomiocárdica, los avances en imagenología han mejorado su abordaje y la reciente introducción de terapias especificas permiten augurar cambios significativos en el pronóstico. El tratamiento difiere según el tipo de amiloide involucrado y su resultado depende de la instauración precoz de este, por lo cual resulta esencial un diagnóstico preciso y temprano. El centellograma cardíaco con fosfatos marcados (99mTc-PYP u otros), ampliamente disponible y de relativo bajo costo, se considera en la actualidad como una "biopsia molecular no invasiva" para el diagnóstico de la amiloidosis tipo ATTR, que debe ser usado en conjunto con la investigación de proteínas monoclonales en pacientes con sospecha clínica de la enfermedad.


Amyloidoses are diseases caused by the extracellular deposition of a fibrillar and insoluble protein material called amyloid, which can be linked either to light chains (AL) or transthyretin (TTR). Cardiac amyloidosis causes a progressive restrictive cardiomyopathy characterized by heart failure with relatively preserved systolic function, which is associated with high mortality. Although a definitive diagnosis is traditionally based on endomyocardial biopsy, advances in cardiac imaging have improved its approach, and the recent introduction of specific therapies predicts significant changes in prognosis. Since treatment differs according to the type of amyloid involved and the results depend on a prompt implementation, an accurate and early diagnosis is essential. Cardiac scintigraphy with labeled phosphates (99mTc-PYP or others), widely available and relatively inexpensive, is currently considered a "noninvasive molecular biopsy" for the diagnosis of ATTR type amyloidosis, which should be used in conjunction with investigation of monoclonal proteins in patients with clinical suspicion of the disease.


As amiloidoses são doenças causadas pela deposição patológica extracelular de um material proteico fibrilar e insolúvel, denominado amiloide, que pode estar ligado a cadeias leves (AL) ou transtirretina (TTR). A amiloidose cardíaca causa cardiomiopatia restritiva progressiva caracterizada por insuficiência cardíaca com função sistólica relativamente preservada, que está associada a alta mortalidade. Embora o diagnóstico definitivo seja tradicionalmente baseado na biópsia endomiocárdica, os avanços nos exames de imagem aprimoraram sua abordagem e a recente introdução de terapias específicas pode predizer mudanças significativas no prognóstico. O tratamento varia de acordo com o tipo de amiloide envolvida e seu resultado depende do início precoce, por isso um diagnóstico preciso e precoce é essencial. A cintilografia cardíaca com fosfatos marcados (99mTc-PYP ou outros), amplamente disponível e relativamente econômico, é atualmente considerada uma "biópsia molecular não invasiva" para o diagnóstico de amiloidose do tipo ATTR, que deve ser usada em conjunto com a investigação de proteínas monoclonais em pacientes com suspeita clínica da doença.


Subject(s)
Humans , Radionuclide Imaging/methods , Technetium Tc 99m Pyrophosphate , Radiopharmaceuticals , Amyloidosis/diagnostic imaging , Cardiomyopathies/diagnostic imaging , Radioactive Tracers , Predictive Value of Tests
2.
Rev. cir. (Impr.) ; 74(3): 309-317, jun. 2022. ilus
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1407911

ABSTRACT

Resumen Los avances en la cirugía hepática de los últimos años han permitido resecciones hepáticas más extensa y complejas para el tratamiento de diferentes patologías del hígado sin un aumento excesivo de la morbimortalidad perioperatoria. El desarrollo de diferentes técnicas, tecnologías y herramientas para la evaluación preoperatoria han mejorado la planificación quirúrgica con el uso por ejemplo de las tecnologías audiovisuales e impresión de modelos en 3 dimensiones (3D) de alta fidelidad. Otros avances, han permitido realizar una mejor evaluación funcional del parénquima hepático y una caracterización más precisa de las lesiones con el uso por ejemplo de verde de indocianina, cintigrafía hepática y resonancia magnética con contraste hepatoespecífico. Este artículo describe algunos de los nuevos avances en la evaluación y planificación preoperatoria en cirugía hepática.


Advances in liver surgery in recent years have made it possible to achieve more extensive and complex liver resections for the treatment of different liver diseases without an excessive increase in perioperative morbidity and mortality. The development of different techniques, technologies and tools for preoperative evaluation have improved surgical planning with the use, for example, of audiovisual technologies and printing of high-fidelity 3-dimensional (3D) models. Other advances have allowed a better functional evaluation of the liver parenchyma and a more precise characterization of the lesions with the use, for example of indocyanine green or liver scintigraphy and magnetic resonance with hepatospecific contrast. This article describes some of the new advances in preoperative evaluation and planning in liver surgery.


Subject(s)
Humans , Bile Duct Neoplasms/surgery , Liver Neoplasms/surgery , Magnetic Resonance Spectroscopy , Radionuclide Imaging , Liver Failure , Elasticity Imaging Techniques , Printing, Three-Dimensional , Hepatectomy , Indocyanine Green
4.
Article in Chinese | WPRIM | ID: wpr-939659

ABSTRACT

OBJECTIVES@#To study the early clinical efficacy of combined therapy of stage 4 neuroblastoma.@*METHODS@#A retrospective analysis was performed on the medical data and follow-up data of 14 children with stage 4 neuroblastoma who were diagnosed in Hong Kong University-Shenzhen Hospital from January 2016 to June 2021.@*RESULTS@#The median age of onset was 3 years and 7.5 months in these 14 children. Among these children, 9 had positive results of bone marrow biopsy, 4 had N-Myc gene amplification, 13 had an increase in neuron-specific enolase, and 7 had an increase in vanilmandelic acid in urine. Based on the results of pathological examination, differentiated type was observed in 6 children, undifferentiated type in one child, mixed type, in one child and poorly differentiated type in 6 children. Of all the children, 10 received chemotherapy with the N7 regimen (including 2 children receiving arsenic trioxide in addition) and 4 received chemotherapy with the Rapid COJEC regimen. Thirteen children underwent surgery, 14 received hematopoietic stem cell transplantation, and 10 received radiotherapy. A total of 8 children received Ch14.18/CHO immunotherapy, among whom 1 child discontinued due to anaphylactic shock during immunotherapy, and the other 7 children completed Ch14.18/CHO treatment without serious adverse events, among whom 1 child was treated with Lu177 Dotatate 3 times after recurrence and is still undergoing chemotherapy at present. The median follow-up time was 45 months for all the 14 children. Four children experienced recurrence within 2 years, and the 2-year overall survival rate was 100%; 4 children experienced recurrence within 3 years, and 7 achieved disease-free survival within 3 years.@*CONCLUSIONS@#Multidisciplinary combined therapy is recommended for children with stage 4 neuroblastoma and can help them achieve better survival and prognosis.


Subject(s)
Child , Child, Preschool , Humans , Infant , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Neuroblastoma/drug therapy , Positron-Emission Tomography , Radionuclide Imaging , Retrospective Studies , Treatment Outcome
5.
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci Torres; Accorsi, Tarso Augusto Duenhas; Gualandro, Danielle Menosi; Oliveira Junior, Múcio Tavares de; Caramelli, Bruno; Kalil Filho, Roberto. Manual da residência em cardiologia / Manual residence in cardiology. Santana de Parnaíba, Manole, 2 ed; 2022. p.921-927, ilus, tab.
Monography in Portuguese | LILACS | ID: biblio-1353766
7.
Braz. J. Pharm. Sci. (Online) ; 58: e191058, 2022. tab
Article in English | LILACS | ID: biblio-1383991

ABSTRACT

Abstract Whole-body bone scintigraphy (WB-BS) is used for detecting and monitoring metastatic spread of prostate cancer (PCa) and to investigate bone pain episodes. To investigate the impact of a positive WB-BS on pain-relieving medicine prescription in PCa patients, a single-center, retrospective cohort study with PCa patients classified as positive for bone metastases (BM) by WB-BS was conducted. Demographic, clinical, and ambulatory pain-relieving medicine prescription data were evaluated. Pain-relieving medicines were categorized according to the WHO 'Analgesic Ladder'. Regimens adopted before and after WB-BS were compared. Differences were considered significant at p<0.05. A total of 180 PCa patients were diagnosed with BM, 64.4% of whom were ≥65 years of age. Thirty-three patients were prescribed analgesics only after WB-BS, mostly including NSAIDs and weak opioids. Pain-relieving prescription changed after WB-BS in patients with prescriptions before and after WB-BS, with a reduction in NSAIDs and adjuvants and an increase in weak and strong opioids. In addition, 40% of patients with WHO analgesic step 1 drugs and 21.7% of patients with WHO step 2 drugs before WB-BS changed to other WHO steps after WB-BS. Pain-relieving prescriptions changed after a positive WB-BS, providing evidence that it could contribute to clinical management of painful metastatic PCa patients.


Subject(s)
Humans , Male , Adult , Patients/classification , Prostatic Neoplasms/pathology , Radionuclide Imaging/instrumentation , Retrospective Studies , Neoplasm Metastasis/diagnosis , Pharmaceutical Preparations , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Diagnosis , Analgesics/administration & dosage , Analgesics, Opioid/adverse effects
10.
Rev. méd. Chile ; 149(5): 790-795, mayo 2021. tab, ilus
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1389521

ABSTRACT

Sjögren Syndrome (SS), a slowly Progressive disease that has unified, validated diagnostic criteria, with excellent evidence and performance in adults, but not in adolescents. We report a 17 year old teenager with a family history of SS in his sister and mother. He presented with fever and fatigue. He had an elevated C reactive protein, leukopenia, positive antinuclear and anti-Rho antibodies and rheumatoid factor. A scintigraphy showed a severe salivary gland dysfunction. The syndrome in this patient had a pediatric clinical behavior despite his proximity to adulthood.


Subject(s)
Humans , Male , Child , Adolescent , Adult , Sjogren's Syndrome/diagnosis , Radionuclide Imaging
11.
Rev. colomb. cardiol ; 28(2): 197-199, mar.-abr. 2021. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1341284

ABSTRACT

Al editor: Clásicamente se ha considerado la amiloidosis cardiaca como una afección rara, con un amplio espectro de síntomas que requiere un alto índice de sospecha. Sin embargo, los estudios han demostrado que la amiloidosis cardiaca por transtiretina (TTR) es más común de lo que previamente se creía1,2. Las características clínicas que se han asociado a la amiloidosis cardiaca por TTR son el sexo masculino, la edad avanzada, la hipertrofia concéntrica y la función ventricular izquierda preservada1. Se realizó un análisis descriptivo retrospectivo de las gammagrafías solicitadas en nuestro centro para descartar amiloidosis cardiaca por TTR desde septiembre de 2016 hasta noviembre de 2019. En dicho periodo se realizaron 39 gammagrafías, con una tendencia al alza en los últimos meses. Los objetivos fueron evaluar las gammagrafías solicitadas y conocer el porcentaje de gammagrafías diagnósticas de amiloidosis por TTR, establecer qué características son más frecuentes en los pacientes con amiloidosis por TTR en nuestra población de referencia y analizar las características diferenciales de las distintas posibilidades diagnósticas. Del total de las pruebas, 22 (56.4% de la muestra) mostraron una captación de grado 2-3 de Perugini, diagnóstica de amiloidosis por TTR. De acuerdo con las recomendaciones de diagnóstico no invasivo de amiloidosis cardiaca por TTR3, se descartó la presencia de pico monoclonal. Únicamente se realizó estudio genético a 10 pacientes, en dos de los cuales se detectó una mutación patogénica (Val50Met y variante patogénica c.290C>A en heterocigosis); los ocho restantes no mostraron mutaciones en el estudio molecular del gen TTR.


Subject(s)
Humans , Male , Aged, 80 and over , Amyloidosis , Prealbumin , Radionuclide Imaging , Diagnosis
12.
Rev. chil. reumatol ; 37(1): 23-33, 2021. ilus, tab
Article in Spanish | LILACS | ID: biblio-1400380

ABSTRACT

Introducción: El dolor musculoesquelético (ME) es un motivo de consulta común en la infancia originado en su mayoría por causas banales. Entre las causas menos frecuentes encontramos las patologías reumatológicas y neoplásicas. Se presentan tres casos clínicos que debutaron con artritis o artralgia en los cuales el diagnóstico final fue neoplásico. Casos clínicos: el primer caso fue una Leucemia Linfoblástica Aguda (LLA) de alto riesgo, el segundo caso fue un sarcoma de Ewing y el tercer caso fue una LLA común. Dos de los casos tuvieron evolución desfavorable con fallecimiento. Revisión de la literatura: Se describen hallazgos que deben hacer sospechar una causa neoplásica tales como el dolor ME desproporcionado, alteraciones en el hemograma, velocidad de eritrosedimentación globular y lactato deshidrogenasa elevados, y radiografía con alteraciones sugerentes. Conclusiones: Frente a un dolor ME en el niño se debe tener presente las causas neoplásicas a pesar de su baja frecuencia dado su mal pronóstico.


Introduction: Musculoskeletal (MS) pain is a common complaint in childhood, usually caused by trivial ailments. Among less frequent causes we may find rheumatological and neoplastic pathologies. We present 3 clinical cases in which a rheumatological cause was initially suspected, as they started out with arthritis or arthralgia, but where the diagnosis was finally a neoplasm. Clinical cases: the first case was a high-risk Acute Lymphoblastic Leukemia (ALL), the second case was a Ewing's sarcoma, and the third case was a common ALL. Two of the cases had unfavourable outcomes and passed away. Literature review: Findings that should make us suspect neoplastic causes are disproportionate MS pain, altered hemogram, elevated erythrocyte sedimentation rate and lactate dehydrogenase, and an x ray with suggestive alterations. Conclusions: When faced with MS pain in children, neoplastic causes must be taken into account despite their low frequency given the poor prognosis associated with the diagnosis.


Subject(s)
Humans , Male , Child , Musculoskeletal Diseases/etiology , Musculoskeletal Diseases/diagnostic imaging , Hematologic Neoplasms/complications , Radiography , Radionuclide Imaging , Clinical Laboratory Techniques , Diagnosis, Differential , Musculoskeletal Pain/etiology
14.
Rev. colomb. radiol ; 32(2): 5554-5557, jun. 2021. imag
Article in English, Spanish | LILACS | ID: biblio-1427517

ABSTRACT

En la era de la medicina personalizada y de precisión, enfocada en mejorar la atención en salud aprovechando al máximo las oportunidades que ofrecen los desarrollos biomédicos, tecnológicos, sociales y económicos de la actualidad, han aparecido nuevos términos como el de teranóstico. Este término nace de la fusión de los conceptos de terapia y diagnóstico y, aunque fue propuesto en años recientes, hace referencia a un abordaje que se ha utilizado desde hace mucho tiempo (1). El teranóstico consiste en una metodología donde el abordaje diagnóstico se hace enfocado hacia la intervención terapéutica individualizada, buscando proporcionar los mejores desenlaces para el paciente. El área de la medicina nuclear ha sido pionera en el teranóstico, pues el primer tratamiento basado en este concepto se realizó con yodo radiactivo (131I) en pacientes con patología tiroidea. Actualmente, con los avances en imagen molecular e imágenes con genes reporteros (2), cada vez se encuentran disponibles más agentes teranósticos para proporcionar terapias individualizadas o "lesionalizadas", como se han empezado a llamar más recientemente (3). En la presente revisión se expone el abordaje teranóstico en medicina nuclear, enfatizando en el funcionamiento, las aplicaciones más frecuentes y la experiencia que se tiene en Colombia.


In the era of personalized and precision medicine, focused on improving health care by making the most of the opportunities offered by current biomedical, technological, social and economic developments, new terms such as theranostic have appeared. This term was born from the fusion of the concepts of therapy and diagnosis and, although it was proposed in recent years, it refers to an approach that has been used for a long time (1). Theranostic consists of a methodology where the diagnostic approach is focused on individualized therapeutic intervention, seeking to provide the best outcomes for the patient. The area of nuclear medicine has been a pioneer in theranostic, since the first treatment based on this concept was performed with radioactive iodine (131I) in patients with thyroid disease. Currently, with advances in molecular imaging and reporter gene imaging (2), more and more theranostic agents are available to provide individualized or "lesionalized" therapies, as they more recently have come to be called (3). In this review, the theranostic approach in nuclear medicine is exposed, emphasizing how it works, what are the most frequent applications and what experience we have in Colombia


Subject(s)
Theranostic Nanomedicine , Radionuclide Imaging , Positron Emission Tomography Computed Tomography , Nuclear Medicine
15.
Article in English | AIM | ID: biblio-1342407

ABSTRACT

The ingestion of smoked foods has been linked to the development of cancer. Polycyclic aromatic hydrocarbons have been recognized as carcinogenic compounds which contaminate smoked foods; their ingestion has been linked to the development of cancers such as breast cancer. Breast cancer may be evaluated using the nuclear bone scan as an imaging modality. This study reviewed bone scan results of patients with a positive history of consumption of smoked foods who presented at a Nuclear Medicine facility in South-West Nigeria. Our results show a significant association between a positive history of consumption of smoked foods and the presence of advanced breast cancer on the bone scan ((χ2 = 11.190, p = 0.001, df = 2; Crude Odds Ratio (95% CI) = 1.692 (1.242-2.304). Thus, those patients with a history of eating smoked foods have between 50-100% increase in the risk of having abnormal scan findings. In a logistic regression, this association was retained (AOR=0.591 (0.434-0.805). Recommendations are made to address the significance of these findings


Subject(s)
Humans , Polycyclic Aromatic Hydrocarbons , Nuclear Medicine , Breast Neoplasms , Radionuclide Imaging , Food
16.
Article in English | WPRIM | ID: wpr-879947

ABSTRACT

Neuroendocrine tumors are a type of heterogeneous tumors originating from neuroendocrine cells derived from the neural crest,which can secrete a variety of amines and peptide hormones.Based on different molecular biomarkers,histologic types and differentiation degrees,individualized nuclear imaging can provide information for the early diagnosis,clinical staging,treatment guidance,and detection of the recurrence and metastasis of neuroendocrine tumor. In this paper,we review the development and application of nuclear medicine molecular imaging probes such as glucose analogs,somatostatin analogues,amine precursors,hormone analogs and enzyme inhibitors in the diagnosis and treatment of neuroendocrine tumors.


Subject(s)
Humans , Diagnostic Imaging , Molecular Probes , Neoplasm Recurrence, Local , Neuroendocrine Tumors/diagnostic imaging , Radionuclide Imaging
17.
Article in Chinese | WPRIM | ID: wpr-879846

ABSTRACT

OBJECTIVE@#To study the clinical features of vesicoureteral reflux (VUR) in children with neurogenic bladder (NB), and to provide a reference for its early diagnosis and treatment.@*METHODS@#Clinical data were collected from 26 children with NB and urinary tract infection who were admitted to the Department of Pediatric Nephrology from January 2014 to December 2019. According to the presence or absence of VUR, the children were divided into a VUR group with 11 children and a non-VUR group with 15 children. Clinical features were compared between the two groups.@*RESULTS@#Compared with the non-VUR group, the VUR group had a significantly higher proportion of children with non-@*CONCLUSIONS@#When NB children have the clinical manifestations of non-


Subject(s)
Child , Humans , Infant , Creatinine , Radionuclide Imaging , Urinary Bladder, Neurogenic/etiology , Urinary Tract Infections/etiology , Vesico-Ureteral Reflux/diagnostic imaging
18.
Rev. colomb. reumatol ; 27(supl.2): 102-108, oct.-dic. 2020. graf
Article in Spanish | LILACS | ID: biblio-1341345

ABSTRACT

RESUMEN El diagnóstico del síndrome de Sjögren se basa en los criterios del consenso americano y europeo (AECG), sin embargo, en muchas oportunidades no se alcanza a detectar el compromiso glandular o extraglandular. Presentamos la evidencia de la utilidad de la gammagrafía con los análogos de somatostatina radiomarcados como prueba novedosa en el acercamiento diagnóstico al compromiso glandular y extraglandular del síndrome de Sjögren.


ABSTRACT Sjögren syndrome is diagnosed using American European Consensus Group (AECG) criteria, although frequently these criteria are not enough to detect the glandular and extra-glandular compromise. Evidence is presented on the use of whole body somatostatin scintigraphy as a novel probe in the diagnostic approach to the glandular and extra-glandular compromise in Sjögren s syndrome.


Subject(s)
Humans , Somatostatin , Sjogren's Syndrome , Diagnosis , Radionuclide Imaging , Consensus , Molecular Imaging
19.
Arch. cardiol. Méx ; 90(3): 259-265, Jul.-Sep. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1131042

ABSTRACT

Resumen Antecedentes y objetivo: La amiloidosis cardíaca es una entidad que permanece infradiagnosticada, a pesar de los avances recientes en su diagnóstico y tratamiento. El objetivo de este estudio es revisar una serie de casos de amiloidosis cardíaca para describir los principales datos clínicos y los hallazgos en las pruebas de imagen. Materiales y métodos: Estudio retrospectivo de pacientes con diagnóstico principal o secundario de amiloidosis cardíaca en los informes de alta de pacientes hospitalizados en este centro desde 2006 hasta 2016. Se revisaron los datos clínicos de los pacientes, así como las pruebas de imagen (ECG, ecocardiograma, gammagrafía cardíaca, resonancia magnética cardíaca). Se realizó seguimiento de los pacientes hasta enero de 2018. Resultados: Se analiza a 30 pacientes (20 varones) con media de 65 años. Los principales datos ecocardiográficos fueron dilatación biauricular, disfunción diastólica e hipertrofia ventricular izquierda (HVI) en un 97%. Sólo el 6.7% cumplía criterios de HVI en el electrocardiograma. Hasta un 33% tenía disfunción sistólica. Se realizó gammagrafía y resonancia magnética cardíaca en un 33%. La supervivencia a los 12 meses fue de 61%. Conclusión: La presencia de insuficiencia cardíaca, fibrilación auricular o trastornos de conducción junto a datos ecocardiográficos indicativos debe alertar al clínico. Otros datos como disfunción sistólica o sexo femenino no deben disminuir la sospecha. El estudio debe completarse con gammagrafía y resonancia magnética cardíaca, ya que el diagnóstico temprano tiene implicaciones pronósticas y terapéuticas.


Abstract Background and objective: Cardiac amyloidosis is an entity that remains underdiagnostic, despite recent advances in its diagnosis and treatment. The aim of this study is to review a series of diagnosed cases of cardiac amyloidosis to describe the main clinical data and the findings in the imaging tests. Materials and methods: Retrospective study of patients with primary or secondary diagnosis of cardiac amyloidosis in discharge reports of patients hospitalized in our center from 2006 to 2016. The clinical data of the patients were reviewed, as well as the imaging tests (ECG, echocardiogram, cardiac scintigraphy, cardiac magnetic resonance). Patients were followed until January 2018. Results: We analyze 30 patients (20 men) with an average of 65 years. The main echocardiographic data were biatrial dilatation, diastolic dysfunction and left ventricular hypertrophy (LVH) in 97%. Only 6.7% met criteria for LVH in the electrocardiogram. Up to 33% had systolic dysfunction. Scintigraphy and cardiac magnetic resonance were performed in 33%. Survival at 12 months was 61%. Conclusion: The presence of heart failure, atrial fibrillation or conduction disorders with suggestive echocardiographic data should alert the clinician. Other data such as systolic dysfunction or female sex should not decrease the suspicion. The study should be completed with gammagraphy and cardiac magnetic resonance since early diagnosis has prognostic and therapeutic implications.


Subject(s)
Humans , Male , Female , Aged , Heart Diseases/diagnosis , Amyloidosis/diagnosis , Magnetic Resonance Imaging , Echocardiography , Radionuclide Imaging , Retrospective Studies , Follow-Up Studies , Electrocardiography , Heart Diseases/physiopathology , Amyloidosis/physiopathology
20.
Rev. Assoc. Med. Bras. (1992) ; 66(3): 345-352, Mar. 2020. graf
Article in English | LILACS, SES-SP | ID: biblio-1136196

ABSTRACT

SUMMARY Cardiac amyloidosis is an infiltrative disease which requires a high degree of clinical suspicion for appropriate diagnosis. Early diagnosis and the definition of the type of amyloidosis play a key role in the early treatment and prognosis of this disease. In this context, the use of cardiac biomarkers such as troponins and NT-proBNT associated with analysis by multimodality imaging methods like echocardiographic techniques such as strain, nuclear medicine, and cardiovascular resonance imaging have an increasing role in patients with cardiac amyloidosis. This article details the role of non-invasive diagnostic methods in patients with cardiac amyloidosis.


RESUMO A amiloidose cardíaca é uma doença infiltrativa que exige um alto grau de suspeição clínica para o diagnóstico apropriado. O diagnóstico precoce e a definição do subtipo de amiloidose têm um papel fundamental para a terapêutica e prognóstico desta doença. Nesse contexto, o emprego de biomarcadores cardíacos como as troponinas e NT-proBNT associados à análise por métodos de imagem multimodalidade por técnicas ecocardiográficas atuais como o strain, medicina nuclear e a ressonância magnética cardíaca têm papel crescente em pacientes com amiloidose. Este artigo detalha a utilização dos métodos não invasivos para a avaliação de pacientes com amiloidose cardíaca.


Subject(s)
Humans , Amyloidosis/diagnosis , Prognosis , Echocardiography , Magnetic Resonance Spectroscopy , Biomarkers , Radionuclide Imaging , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL